CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) today will provide an update for the investment community on the Company’s research and development pipeline, highlighting a broad and innovative portfolio that includes six programs in registration trials.
